

Data Sheet

Anti-NY-ESO-1 Antibody, Mouse Monoclonal

Clone E978, purified from hybridoma cell culture

N2038

Product Description

Anti-NY-ESO-1 Monoclonal (mouse IgG1 isotype) is derived from the hybridoma E978 produced by the fusion of mouse myeloma cells (SP2/0) and splenocytes from BALB/c mice immunized with human recombinant NY-ESO-1 (Gene ID: 1485). The isotype is determined using a double diffusion immunoassay using Mouse Monoclonal Antibody Isotyping Reagents, Cat. No. ISO2.

Monoclonal Anti-NY-ESO-1 recognizes human¹⁻³ NY-ESO-1. The antibody may be used in ELISA, immunoblotting (~ 23 kDa),¹⁻² and immunohistochemistry.²⁻³

Cancer/testis (CT) antigens are the protein products of genes that are activated in a wide variety of tumors and can elicit autologous cellular and humoral immune responses. Their normal expression is restricted to male germ cells in the testis, and they are not expressed in adult somatic tissues. Therefore, CT antigens are promising candidates for cancer immunotherapy.⁴ Approximately 20 CT antigens or antigen families have been identified to date. NY-ESO-1 is a CT protein to which cell-mediated immune response has been demonstrated. The gene was cloned from an esophageal carcinoma cDNA expressing library using autologous patient serum. The protein is expressed in normal testis and to a much lower extent in placenta, ovary and uterus. However, it is mainly expressed in many different cancers.⁵ For example, patients with melanoma contain tumor-infiltrating lymphocytes cells (TILs) that recognized NY-ESO-1 protein.⁶ The expression of genes encoding CT antigens was examined in sporadic medullary thyroid carcinoma. The expression of NY-ESO-1 was found in 65 percent of the samples and correlated with tumor recurrence in primary MTC tumors.⁷ Furthermore, high frequency of expression was found in breast cancer especially in benign lesions² and in multiple myeloma.⁸ Due to its wide expression in different cancers, NY-ESO-1 protein was used as a vaccine in cancer patients. A humoral and cellular response was obtained in many patients.

Furthermore, in patients with melanoma, the natural course of the disease was favorably influenced by this treatment.⁹

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative.

Antibody concentration: ~ 1 mg/mL

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: A working concentration of 1-2 µg/mL is recommended using SKMel-37 total cell extract.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining optimal working dilutions by titration.

References

1. Stockert, E., et al., J. Exp. Med., 187, 1349-1354 (1998).
2. Sugita, Y., et al., Cancer Res., 64, 2199-2204 (2004).
3. Jungbluth, A.A., et al., Blood, 106, 167-174 (2005).
4. Scanlan M.J., et al., Immunol. Rev., 188, 22-32 (2002).
5. Chen, Y.T., et al., Proc. Natl. Acad. Sci. USA, 94, 1914-1918 (1997).
6. Khong, H.T., and Rosenberg, S.A., J. Immunol., 168, 951-956 (2002).
7. Maio, M., et al., J. Clin. Endocr. Metab., 88, 748-754 (2003).
8. Szmania, S., et al., Leuk. Lymphoma, 47, 2037-2048 (2006).
9. Jager, E., et al., Proc. Natl. Acad. Sci. USA, 103, 14453-14458 (2006).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices.

The life science business of Merck operates
as MilliporeSigma in the U.S. and Canada.

Merck and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

N2038dat Rev07/22

